Refine Results
Sort By
From
To
Page 1
Page 1
Management of atopic dermatitis : Methods and challenges
This new edition builds upon the foundational knowledge covered in the first edition, covering the epidemiology, pathogenesis, and clinical presentation of atopic dermatitis in both pediatric and adult patients. It provides an overview of the mechanism and presentation of atopic dermatitis and focuses on the management methods experienced dermatologists have used to successfully manage atopic dermatitis. The book includes new chapters describing the special considerations for atopic dermatitis in skin of color patients, dedicated chapters on topical and oral prescription management reflected the latest FDA-approved treatments, and also a chapter covering the updated guidelines from the American Academy of Dermatology. A final chapter includes updates on the future of atopic dermatitis treatment.
Machine learning for neurodegenerative disorders : advancements and applications
Explores the application of machine learning to the understanding, early diagnosis, and management of neurodegenerative disorders. With a specific focus on its role in ongoing clinical trials, the book covers essential topics such as data collection, pre-processing, feature extraction, model development, and validation techniques. It delves into the applications of neuroimaging techniques like magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) in the diagnosis and understanding of neurodegenerative disorders. Additionally, the book examines various machine-learning algorithms employed for biomarker discovery in neurodegenerative disorders. It highlights the role of neuroinformatics and big data analysis in advancing the understanding and management of neurodegenerative disorders. Furthermore, the book reviews future prospects and presents the ethical considerations and regulatory challenges associated with implementing machine learning approaches in the diagnosis, treatment, and prevention of neurodegenerative disorders.
Leptomeningeal Metastases
Leptomeningeal Metastases provides the reader with an overview of the state-of-the-art therapy for the leptomeningeal patient with additional information on epidemiology, symptom management, new clinical trials, and current basic research in animal models for experimental therapies. "Leptomeningeal metastases remains a devastating manifestation of hematologic malignancies and solid tumors. Leading figures in the field review the pathophysiology and clinical consequences of this process. State-of-the-art treatment strategies are presented highlighting advances in current management."
Key Clinical Trials in Erectile Dysfunction
Represents a critical appraisal of the major clinical trials that have had a significant impact on clinical research and practice during the last decade. Each trial follows a strict format, starting with reference to the original source of publication, details on the key investigators and their methods of research. The strengths and weaknesses of each trial are discussed as well as their influence on clinical practice. Articles are complemented by a diagrammatic summary of the trial design and the key findings.
Cerebral Hemorrhage
Cerebral hemorrhage is a common and often fatal subtype of stroke. while in the past it has received relatively little attention compared to ischemic stroke, there have been major advances in our understanding of this devastating form of stroke. The papers by world experts cover the field from molecular biology to clinical trials.
Cancer Clinical Trials : Proactive Strategies
The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited.
Biomarkers for alzheimer’s disease drug development
Helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed.
Bioinformatics tools for pharmaceutical drug product development
Presents the latest information on bioinformatics tools, artificial intelligence, machine learning, computational methods, protein interactions, peptide-based drug design, and omics technologies. And include bioinformatics tools for the pharmaceutical sector and the healthcare sector. Bioinformatics brings a new era in research to accelerate drug target and vaccine design development, improving validation approaches as well as facilitating and identifying side effects and predicting drug resistance. As such, this will aid in more successful drug candidates from discovery to clinical trials to the market, and most importantly make it a more cost-effective process overall.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Antiangiogenic Agents in Cancer Therapy
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Analyzing T cell responses : How to analyze cellular immune responses against tumor associated antigens
Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer
An introduction to clinical trials
An Introduction to clinical trials is a concise step-by-step guide to the principles and practices of clinical trials for those studying clinical trials or new to working on one. Clinical trials are critical to the progress of medicine and improving healthcare / as they evaluate whether new treatments and interventions work. They are also complex / multidisciplinary projects that integrate science / ethics / and legal requirements in the conduct of medical research.
AI in disease detection : Advancements and applications
Discusses the integration of artificial intelligence to revolutionize disease detection approaches, with case studies of AI in disease detection as well as insight into the opportunities and challenges of AI in healthcare as a whole. The book explores a wide range of individual AI components such as computer vision, natural language processing, and machine learning as well as the development and implementation of AI systems for efficient practices in data collection, model training, and clinical validation.
Advancing the Science of Cancer in Latinos
This book gives an overview of the sessions, panel discussions, and outcomes of the Advancing the Science of Cancer in Latinos conference, held in February 2018 in San Antonio, Texas, USA, and hosted by the Mays Cancer Center and the Institute for Health Promotion Research at UT Health San Antonio.
Advances in Radiation Oncology in Lung Cancer
This volume is unique in being devoted solely to the radiation oncology of lung cancer, and will be of great value to all who are involved in the diagnosis and treatment of the disease. Both non-small cell and small cell lung cancer are considered in detail. Current state of the art treatment strategies and novel approaches that promise further improvements in outcome are explained and evaluated, with the aid of high-quality illustrations. Treatment-related toxicity is discussed, and further individual chapters focus on topics such as quality of life studies, prognostic factors and pitfalls in the design and analysis of clinical trials.
Advances in multiple Sclerosis and Experimental Demyelinating Diseases
Challenging Charcot’s hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement.
Leveraging Data Science for Global Health
Explores ways to leverage information technology and machine learning to combat disease and promote health, especially in resource-constrained settings. It focuses on digital disease surveillance through the application of machine learning to non-traditional data sources.
Alzheimers Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors).
